Unlike deletion, the prognostic impact of CDKN2A/B promoter hypermethylation, and, to an even lesser extent, gene body hypermethylation and hydroxymethylation, has not been thoroughly analyzed in BCP-ALL because of the greater extent of promoter hypermethylation in T-ALL (Table 3 and Table 4). The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.